Beijing SH Bio-Tech Corporation

Beijing SH Bio-Tech Corporation (Beijing Sanyouli Heze Biological Technology) is a clinical-stage biotechnology company based in Beijing, China, dedicated to the development of innovative cell therapies and biopharmaceuticals. Established in 2011, the company has pioneered a platform for dental pulp mesenchymal stem cells (DPSCs), with its lead candidate currently in Phase 2 clinical trials for the treatment of chronic periodontitis. Beyond regenerative medicine, the company's pipeline includes a recombinant prothrombin inhibitor (EH) for cardiovascular indications and CAR-T cell therapies for hematological cancers. Beijing SH Bio-Tech operates a 500-square-meter GMP-certified facility for cell preparation and maintains a state-of-the-art stem cell bank. The company leverages strong academic ties with institutions such as Capital Medical University and the Chinese People's Liberation Army General Hospital to drive its R&D efforts.